Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2020

23.04.2020 | Epidemiology

Ovarian removal at or after benign hysterectomy and breast cancer: a nationwide cohort study

verfasst von: Mathilde Gottschau, Susanne K. Kjær, Annette Settnes, Gitte Lerche Aalborg, Annet Bens, Allan Jensen, Christian Munk, Lene Mellemkjær

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Large-scale population-based registry studies investigating the risk of breast cancer after removal of both ovaries at hysterectomy for benign conditions in women with no known genetic predisposition to cancer are needed. We aimed to perform such a study taking into account the age at surgery status and use of hormone replacement therapy (HRT).

Methods

Within the female population of Denmark born 1937–1996, we evaluated breast cancer incidence after unilateral or bilateral oophorectomy concomitant with or after benign hysterectomy in comparison with no surgery and with hysterectomy alone using health registry data during 1978–2016. In a subpopulation followed from 1996, the analyses were stratified according to use of HRT.

Results

We found a reduced risk of breast cancer among women aged < 45 years at bilateral oophorectomy compared with women with hysterectomy alone (HR = 0.78; 95% CI 0.66, 0.92), whereas slightly increased risks were seen in women above 50 years. In the subpopulation, non-users of HRT aged ≥ 50 years at oophorectomy had a HR of 0.74 (95% CI 0.56, 0.98) for breast cancer after bilateral oophorectomy compared with hysterectomy alone.

Conclusions

Our large-scale study covering four decades provides evidence that bilateral oophorectomy performed at young age in women with benign indications for hysterectomy is associated with a reduction in breast cancer risk. The finding of a negative association at older ages in women not using HRT deserves further attention.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Topsoee MF, Ibfelt EH, Settnes A (2016) The Danish Hysterectomy and Hysteroscopy Database. Clin Epidemiol 8:515–520CrossRef Topsoee MF, Ibfelt EH, Settnes A (2016) The Danish Hysterectomy and Hysteroscopy Database. Clin Epidemiol 8:515–520CrossRef
2.
Zurück zum Zitat Nielsen SL, Daugbjerg SB, Gimbel H, Settnes A, Steering Committee of Danish Hysterectomy Database (2011) Use of vaginal hysterectomy in Denmark: rates, indications and patient characteristics. Acta Obstet Gynecol Scand 90:978–984CrossRef Nielsen SL, Daugbjerg SB, Gimbel H, Settnes A, Steering Committee of Danish Hysterectomy Database (2011) Use of vaginal hysterectomy in Denmark: rates, indications and patient characteristics. Acta Obstet Gynecol Scand 90:978–984CrossRef
3.
Zurück zum Zitat Li X, You R, Wang X, Liu C, Xu Z, Zhou J, Yu B, Xu T, Cai H, Zou Q (2016) Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res 22:3971–3981CrossRef Li X, You R, Wang X, Liu C, Xu Z, Zhou J, Yu B, Xu T, Cai H, Zou Q (2016) Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res 22:3971–3981CrossRef
4.
Zurück zum Zitat Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO (2018) Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database System Rev 8:Cd012464 Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO (2018) Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database System Rev 8:Cd012464
5.
Zurück zum Zitat Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRef Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRef
6.
Zurück zum Zitat Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS (2005) Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 106:219–226CrossRef Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS (2005) Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 106:219–226CrossRef
7.
Zurück zum Zitat Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, Berek JS, Manson JE (2013) Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses’ Health Study. Obstet Gynecol 121:709–716CrossRef Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, Berek JS, Manson JE (2013) Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses’ Health Study. Obstet Gynecol 121:709–716CrossRef
8.
Zurück zum Zitat Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, Von Mühlen D (2000) Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 85:645–651PubMed Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, Von Mühlen D (2000) Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 85:645–651PubMed
9.
Zurück zum Zitat Davison SL, Bell R, Donath S, Montalto JG, Davis SR (2005) Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 90:3847–3853CrossRef Davison SL, Bell R, Donath S, Montalto JG, Davis SR (2005) Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 90:3847–3853CrossRef
10.
Zurück zum Zitat Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344:276–285CrossRef Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344:276–285CrossRef
11.
Zurück zum Zitat Sood R, Faubion SS, Kuhle CL, Thielen JM, Shuster LT (2014) Prescribing menopausal hormone therapy: an evidence-based approach. Int J Women's Health 6:47–57CrossRef Sood R, Faubion SS, Kuhle CL, Thielen JM, Shuster LT (2014) Prescribing menopausal hormone therapy: an evidence-based approach. Int J Women's Health 6:47–57CrossRef
12.
Zurück zum Zitat Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses’ Health Study. Obstet Gynecol 113:1027–1037CrossRef Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses’ Health Study. Obstet Gynecol 113:1027–1037CrossRef
13.
Zurück zum Zitat Jacoby VL, Grady D, Wactawski-Wende J, Manson JE, Allison MA, Kuppermann M, Sarto GE, Robbins J, Phillips L, Martin LW et al (2011) Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Arch Intern Med 171:760–768CrossRef Jacoby VL, Grady D, Wactawski-Wende J, Manson JE, Allison MA, Kuppermann M, Sarto GE, Robbins J, Phillips L, Martin LW et al (2011) Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Arch Intern Med 171:760–768CrossRef
14.
Zurück zum Zitat Gaudet MM, Gapstur SM, Sun J, Teras LR, Campbell PT, Patel AV (2014) Oophorectomy and hysterectomy and cancer incidence in the Cancer Prevention Study-II Nutrition Cohort. Obstet Gynecol 123:1247–1255CrossRef Gaudet MM, Gapstur SM, Sun J, Teras LR, Campbell PT, Patel AV (2014) Oophorectomy and hysterectomy and cancer incidence in the Cancer Prevention Study-II Nutrition Cohort. Obstet Gynecol 123:1247–1255CrossRef
15.
Zurück zum Zitat Mytton J, Evison F, Chilton PJ, Lilford RJ (2017) Removal of all ovarian tissue versus conserving ovarian tissue at time of hysterectomy in premenopausal patients with benign disease: study using routine data and data linkage. BMJ 356:j372CrossRef Mytton J, Evison F, Chilton PJ, Lilford RJ (2017) Removal of all ovarian tissue versus conserving ovarian tissue at time of hysterectomy in premenopausal patients with benign disease: study using routine data and data linkage. BMJ 356:j372CrossRef
16.
Zurück zum Zitat Gjerstorff ML (2011) The Danish Cancer Registry. Scand J Public Health 39(7 Suppl):42–45CrossRef Gjerstorff ML (2011) The Danish Cancer Registry. Scand J Public Health 39(7 Suppl):42–45CrossRef
17.
Zurück zum Zitat Blenstrup LT, Knudsen LB (2011) Danish registers on aspects of reproduction. Scand J of Public Health 39(7 Suppl):79–82CrossRef Blenstrup LT, Knudsen LB (2011) Danish registers on aspects of reproduction. Scand J of Public Health 39(7 Suppl):79–82CrossRef
18.
Zurück zum Zitat Jensen VM, Rasmussen AW (2011) Danish education registers. Scand J Public Health 39(7 Suppl):91–94CrossRef Jensen VM, Rasmussen AW (2011) Danish education registers. Scand J Public Health 39(7 Suppl):91–94CrossRef
19.
Zurück zum Zitat Schmidt M, Pedersen L, Sorensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29:541–549CrossRef Schmidt M, Pedersen L, Sorensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29:541–549CrossRef
20.
Zurück zum Zitat Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449–490CrossRef Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449–490CrossRef
21.
Zurück zum Zitat Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M (2017) Data Resource Profile: The Danish National Prescription Registry. Int J Epidemiol 46:798–798fPubMed Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M (2017) Data Resource Profile: The Danish National Prescription Registry. Int J Epidemiol 46:798–798fPubMed
24.
Zurück zum Zitat Zhang P, Li CZ, Jiao GM, Zhang JJ, Zhao HP, Yan F, Jia SF, Hu BS, Wu CT (2017) Effects of ovarian ablation or suppression in premenopausal breast cancer: a meta-analysis of randomized controlled trials. Eur J Surg Oncol 43:1161–1172CrossRef Zhang P, Li CZ, Jiao GM, Zhang JJ, Zhao HP, Yan F, Jia SF, Hu BS, Wu CT (2017) Effects of ovarian ablation or suppression in premenopausal breast cancer: a meta-analysis of randomized controlled trials. Eur J Surg Oncol 43:1161–1172CrossRef
25.
Zurück zum Zitat Boggs DA, Palmer JR, Rosenberg L (2014) Bilateral oophorectomy and risk of cancer in African American women. Cancer Causes Control 25:507–513CrossRef Boggs DA, Palmer JR, Rosenberg L (2014) Bilateral oophorectomy and risk of cancer in African American women. Cancer Causes Control 25:507–513CrossRef
26.
Zurück zum Zitat Von Euler-Chelpin M (2011) Breast cancer incidence and use of hormone therapy in Denmark 1978–2007. Cancer Causes Control 22:181–187CrossRef Von Euler-Chelpin M (2011) Breast cancer incidence and use of hormone therapy in Denmark 1978–2007. Cancer Causes Control 22:181–187CrossRef
27.
Zurück zum Zitat Adelman MR, Sharp HT (2018) Ovarian conservation vs removal at the time of benign hysterectomy. Am J Obstet Gynecol 218:269–279CrossRef Adelman MR, Sharp HT (2018) Ovarian conservation vs removal at the time of benign hysterectomy. Am J Obstet Gynecol 218:269–279CrossRef
Metadaten
Titel
Ovarian removal at or after benign hysterectomy and breast cancer: a nationwide cohort study
verfasst von
Mathilde Gottschau
Susanne K. Kjær
Annette Settnes
Gitte Lerche Aalborg
Annet Bens
Allan Jensen
Christian Munk
Lene Mellemkjær
Publikationsdatum
23.04.2020
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05628-z

Weitere Artikel der Ausgabe 2/2020

Breast Cancer Research and Treatment 2/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.